MBOT - Microbot Medical confirms GLP trial on track to begin later this month
- Microbot Medical ( NASDAQ: MBOT ) is trading 5.5% higher after the company said it shipped multiple Liberty Robotic System devices to a market-leading research laboratory to conduct the Company’s GLP pre-clinical trial.
- The comprehensive trial, which is anticipated to commence later this month, will be performed in the endovascular space at a lab with planning, controlling, monitoring and reporting.
- The Company expects the results of the GLP pre-clinical trial will further validate the successful outcomes from multiple prior animal feasibility studies performed.
For further details see:
Microbot Medical confirms GLP trial on track to begin later this month